Related Experiment Video

Updated: Dec 5, 2025

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

738

Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

Nobuaki Mori1, Mitsuya Katayama1, Shigenari Nukaga2

  • 1Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|October 15, 2020
PubMed

Insights

Triple therapy using hydroxychloroquine, azithromycin, and ciclesonide shows effectiveness in treating COVID-19 pneumonia. Patients experienced clinical improvement within five days of treatment initiation.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Respiratory Medicine

Background:

  • No specific antiviral therapy is currently available for COVID-19.
  • COVID-19 pneumonia presents a significant clinical challenge.
  • Exploring novel therapeutic strategies is crucial for managing severe cases.

Purpose of the Study:

  • To evaluate the effectiveness and safety of a triple therapy regimen for COVID-19 pneumonia.
  • To assess the clinical improvement and adverse effects associated with hydroxychloroquine, azithromycin, and ciclesonide combination therapy.

Main Methods:

  • Retrospective analysis of patients diagnosed with COVID-19 pneumonia.
  • Administration of a triple therapy including hydroxychloroquine, azithromycin, and ciclesonide.
  • Monitoring of clinical condition and adverse events during the treatment period.

Main Results:

  • The triple therapy demonstrated significant effectiveness in improving the clinical condition of patients.
  • Clinical improvement was observed within an average of 5 days following the initiation of therapy.
  • Further analysis is required to fully characterize the safety profile and long-term outcomes.

Conclusions:

  • Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide offers a potential treatment option for COVID-19 pneumonia.
  • The combination therapy led to rapid clinical improvement in the studied patient cohort.
  • Further large-scale clinical trials are warranted to confirm these findings and establish optimal treatment protocols.

Keywords:
AzithromycinCOVID-19CiclesonideHydroxychloroquinePneumoniaReverse transcription-PCRSARS-CoV-2Therapy

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.0K
Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

1.2K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
629
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
464
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
668
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
596
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.1K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K